India has expanded its efforts to make cancer treatment more affordable by regulating trade margins on 137 identified non-scheduled anti-cancer medicines. The National Pharmaceutical Pricing Authority announced the measure following a government notification issued on 17 October 2026, with the revised prices scheduled to become effective on 9 November.
The policy targets medicines that were not previously covered by the same scheduled-drug ceiling-price framework. By regulating trade margins across the distribution and retail chain, the government aims to limit excessive mark-ups that can increase the amount patients pay for cancer medicines.
Editorial Insight
Key Highlights
Important points readers should notice.
Issue/Event: Trade-margin rationalisation for 137 identified non-scheduled anti-cancer medicines.
Location: Nationwide, across applicable medicine supply channels, pharmacies and hospitals.
Authority/Organisation: National Pharmaceutical Pricing Authority, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
Action Taken: The government notified a trade-margin cap of 30% under the applicable drug-pricing framework and scheduled revised prices to take effect on 9 November 2026.
Impact: The government expects the maximum retail prices of the identified medicines to fall by up to 70%, depending on existing price structures. Actual savings will vary by medicine.
According to the Department of Pharmaceuticals, the intervention could reduce the maximum retail prices of the identified medicines by up to 70%. This is an estimated maximum reduction, not a uniform discount applicable to every medicine. The actual change will depend on the existing price and distribution structure of each formulation.
The decision is particularly relevant for patients who require expensive cancer therapies over extended periods. Medicine costs can represent a substantial part of treatment expenditure, alongside hospital charges, diagnostic tests, specialist consultations and other supportive care.
Which Medicines Are Covered?
Editorial Analysis
Why This Matters
Treatment affordability: Lower medicine prices could reduce a portion of the financial burden faced by cancer patients and their families. Price transparency: Updated price lists should help patients compare the applicable prices and identify potential overcharging. Healthcare access: Improved affordability may help some patients obtain prescribed medicines more consistently. Supply continuity: Manufacturers are required to maintain production and supply levels under the announced framework. Implementation: The actual benefit will depend on timely price revisions and compliance by manufacturers, pharmacies and hospitals.
The identified list includes several categories of anti-cancer medicines, including immunotherapy treatments and medicines used in managing complications associated with cancer treatment.
The government has identified medicines such as pembrolizumab, durvalumab and osimertinib among the products expected to become more accessible under the revised pricing framework. The list also includes denosumab, pegfilgrastim and bevacizumab.
These medicines serve different clinical purposes. Some are used in specific cancer-treatment regimens, while others may help manage complications or support treatment. Their suitability depends on the patient's diagnosis, clinical condition and the treating specialist's assessment.
The inclusion of a medicine in the pricing measure does not mean it is appropriate for every cancer patient. Treatment decisions must continue to be made by qualified medical professionals.
How the New Pricing Framework Works
The NPPA has invoked the relevant provisions of the Drugs (Prices Control) Order, 2013, to rationalise trade margins on the identified non-scheduled anti-cancer medicines.
The objective is to regulate the margins applied through the supply and retail chain while preserving the legitimate commercial interests of manufacturers and maintaining medicine availability.
Manufacturers are required to inform the NPPA of revised prices within seven days of publication of the notification. They must also publish updated price lists and communicate the changes to retailers and hospitals.
From 9 November 2026, retailers and hospitals covered by the order must charge the revised applicable prices and display the updated information. State drug controllers are expected to take steps to monitor compliance.
The policy also requires manufacturers to maintain production and supply levels to help prevent artificial shortages arising from the pricing intervention.
Why the November 9 Date Matters
The implementation date gives manufacturers, distributors, pharmacies and hospitals time to update their pricing records and communicate the changes through the supply chain.
Patients and families should check the revised price of a specific medicine rather than assume that every anti-cancer drug will become cheaper by the same percentage. The final price will depend on the formulation and the applicable revised maximum retail price.
Consumers can consult the NPPA website and its Pharma Sahi Daam application to check medicine-price information. Patients should retain prescriptions and purchase receipts and seek clarification from the dispensing pharmacy if the displayed price and billed amount differ.
If a suspected overcharge occurs, consumers can seek clarification from the pharmacy and approach the relevant drug-control authority or NPPA through its available grievance channels.
How This Builds on Earlier Price Controls
The latest intervention builds on a 2019 exercise in which trade margins were rationalised for 42 selected non-scheduled anti-cancer medicines. The government reported that the earlier initiative reduced the maximum retail prices of 526 brands by up to 90%.
The expanded measure applies to a larger identified group of medicines and reflects continuing efforts to address affordability in oncology care.
However, regulating medicine prices is only one part of the broader challenge of making cancer treatment accessible. Patients may still face costs associated with hospitalisation, surgery, radiotherapy, diagnostic procedures, travel and supportive medication.
The practical impact will therefore depend on the actual price reductions, compliance across the supply chain and the availability of the medicines covered by the notification.
What Patients and Families Should Know
Patients should not change or interrupt prescribed treatment because of an anticipated price reduction. Instead, they can ask their oncologist or pharmacist whether their prescribed medicine appears on the applicable list and what revised price will apply from 9 November.
Patients should also distinguish between the active ingredient, the brand name, the strength and the formulation. Two medicines used for similar conditions are not necessarily interchangeable, and substitutions should be made only with appropriate medical guidance.
The government has directed manufacturers to maintain supply levels, but actual availability may vary between locations and healthcare providers. Patients who encounter a shortage should consult their treating team about clinically appropriate options rather than independently changing medication.
The coming weeks will be important in determining how effectively the revised pricing framework reaches patients at pharmacies and hospitals.
